US EditionCleveland Clinic researchers share promising results from experimental breast cancer vaccine trial
The vaccine targeting alpha-lactalbumin was safe and induced immune responses in 74% of participants, supporting a planned Phase II trial to further evaluate efficacy.
- On Thursday, Cleveland Clinic researchers presented Phase I trial results at the San Antonio Breast Cancer Symposium showing the vaccine was safe and induced immune responses in 74% of participants.
- The vaccine targets alpha-lactalbumin, found in most triple-negative breast cancer tumors but absent from normal aging breast tissue, addressing a need for treatments in aggressive TNBC.
- The Phase I trial enrolled 35 patients across three cohorts and determined a maximum tolerated dose with mainly mild injection-site inflammation.
- Anixa Biosciences plans a multicenter Phase 2 trial beginning late next year, which it will perform and direct under license from Cleveland Clinic, projected to last two to three years.
- Built on decades of preclinical work by Vincent Tuohy, Ph.D., supported by philanthropic donors over 12 years, four trial participants experienced cancer recurrence though the study wasn’t designed to assess efficacy.
26 Articles
26 Articles
Researchers expect this vaccine to teach the immune system to attack and destroy tumor cells
Cleveland Clinic reports promising results for breast cancer vaccine from final Phase 1 data
Cleveland Clinic researchers are presenting final Phase 1 data from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.
Preventive TNBC Vaccine Triggers Immune Responses in Phase I Study
Final results from a Phase I clinical study suggest that a preventive vaccine strategy for triple-negative breast cancer (TNBC) may be biologically feasible in humans. Investigators at Cleveland Clinic reported that an experimental vaccine targeting the lactation protein α-lactalbumin was well tolerated and elicited immune responses in most participants across three high-risk groups. The findings (PS4-06-19) were presented at the 2025 San Antoni…
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
